Morgan Stanley Discount Zert ABBV.../ DE000ME6LE64 /
| 6/21/2024 9:19:34 PM | Chg.+0.10 | Bid10:00:34 PM | Ask10:00:34 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 91.35EUR | +0.11% | - Bid Size: - |
- Ask Size: - |
AbbVie Inc | - USD | 12/31/2024 | Call |
GlobeNewswire
12:04 PM
CEREVEL (NASDAQ:CERE) INVESTOR ALERT: Cerevel’s $45 Per Share Offer is Being Investigated by BFA Law...
GlobeNewswire
6/21
Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest C...
GlobeNewswire
6/20
CEREVEL INVESTOR REMINDER: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? Contact BFA Law...
GlobeNewswire
6/20
OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of I...
GlobeNewswire
6/19
OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the B...
GlobeNewswire
6/19
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
GlobeNewswire
6/18
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...
GlobeNewswire
6/18
CEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoi...
GlobeNewswire
6/17
Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, B...
GlobeNewswire
6/15
CEREVEL STOCK NOTICE: Think $45 Per Share is Too Low for Cerevel (Nasdaq: CERE)? Contact BFA Law abo...
GlobeNewswire
6/13
Anima Biotech to Present at the Society for Medicines Research’s Modulating RNA with Oligonucleotide...
GlobeNewswire
6/13
CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investi...
GlobeNewswire
6/13
What Employees at the Fortune Best Workplaces in New York, Chicago, Texas, and the Bay Area Value Mo...
GlobeNewswire
6/12
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, ...
GlobeNewswire
6/12
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in ...
GlobeNewswire
6/11
CEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urg...
GlobeNewswire
6/8
CEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into ...
GlobeNewswire
6/5
CEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law abou...
GlobeNewswire
6/5
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...
